No Data
Towa Pharmaceutical Revises Forecast for Fiscal 2024
JT, 1Q operating profit increased by 15.3% to 248.7 billion yen.
JT <2914> announced that its performance for the first quarter of the fiscal year ending December 2025 showed a revenue increase of 11.7% year-on-year to 826.9 billion yen, and an operating profit increase of 15.3% to 248.7 billion yen. The price increases for cigarettes in Overseas markets such as the Philippines, Russia, and the UK contributed to the revenue growth, as well as the acquisition of the U.S. Vector Group Ltd, which specializes in rolled tobacco, in October last year. For the fiscal year ending December 2025, revenue is projected to increase by 3.9% from the previous period to 3 trillion 273 billion yen, operating profit.
TOWA Pharmaceutical: Notice regarding revisions to earnings forecasts
TOWA Pharmaceutical To Go Ex-Dividend On March 28th, 2025 With 40 JPY Dividend Per Share
March 27th (Japan Standard Time) - $TOWA Pharmaceutical(4553.JP)$ is trading ex-dividend on March 28th, 2025.Shareholders of record on March 31st, 2025 will receive 40 JPY dividend per share. The ex-
Towa Pharmaceutical Enhances Internal Control System
<Rating Change Observation> Upgraded rating for New and Towa Pharmaceutical / JR East, downgraded rating for Eisai, etc.
◎New and resumed Kansai Electric Power <1942.T> - The domestic mid-sized company has moved up three levels to the highest position. Kinden <1944.T> - The domestic mid-sized company has moved up three levels to the highest position. Towa Pharmaceutical <4553.T> - The bank-affiliated company has moved up three levels to the highest position. Sawai GHD <4887.T> - The bank-affiliated company has moved up three levels to the highest position. Shimadzu <7701.T> - The domestic mid-sized company has moved up five levels to the highest position. ◎Upgraded Hot Stock <3196.T> - The domestic medium-sized company has moved up three levels to the highest position. Daikin <6367.T> - The domestic large company is in the 2nd position of five levels.
